Emerging data suggest Retatrutide , a dual agonist targeting both GLP-1 and GIP , may represent a promising step forward for body treatment. Preliminary human tests have demonstrated impressive https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026